| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Fda Clears Thumb Implant For Osteoarthritis
Posted on 06/19/2007 20:51:59 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Small Bone Innovations (SBi), a New York, NY, company focused exclusively on small bone and joint orthopedic devices, has received FDA clearance to market a new implant for osteoarthritis at the base of the thumb. The product, Artelon CMC Spacer Arthro, is an extension of SBi’s existing line of carpal metacarpal spacers for base-of-thumb osteoarthritis.
SBI, which prides itself on developing products with guidance from orthopedic surgeons, designed this Artelon spacer to allow minimally invasive, arthroscopic implantation in the joint between the first metacarpal and the trapezium. The idea is that by avoiding violation of the joint capsule, patients will experience longer maintenance of joint stability, faster recovery and less pain.
In a statement issued by SBi, one of the company’s consulting surgeons, Dr. Randall Culp from Thomas Jefferson University in Philadelphia, said, “Arthroscopic implantation of an Artelon spacer is a good option for younger, more active, people who may be reluctant to undergo invasive surgery for a condition that is increasingly common among this group.”
And SBi’s CEO, Anthony Viscogliosi, points out that the device allows patients to undergo therapy earlier in the disease progression, and eliminates or minimizes the sacrifice of healthy tissue in other carpal metacarpal joint procedures that commonly include removal of the trapezium and harvesting tendon from the forearm.
Since being founded in 2005 by Viscogliosi Bros. — the musculoskeletal-focused venture capital firm created SBi by acquiring established companies in the orthopedic field, to create a single source of products for surgeons specializing in small bones and joints or limbs — the company has been on a role. Last year, it received five new FDA 510(k) clearances and completed eight M&A licensing and distribution deals; 19 new products were introduced. In April, SBi secured a $20 million debt facility financed by the Drawbridge Special Opportunities Fund.
Med Tech Sentinal is a regular contributor to BioHealthInvestor.com
________________
Med Tech Sentinel
Small Bone Innovations (SBi), a New York, NY, company focused exclusively on small bone and joint orthopedic devices, has received FDA clearance to market a new implant for osteoarthritis at the base of the thumb. The product, Artelon CMC Spacer Arthro, is an extension of SBi’s existing line of carpal metacarpal spacers for base-of-thumb osteoarthritis.
SBI, which prides itself on developing products with guidance from orthopedic surgeons, designed this Artelon spacer to allow minimally invasive, arthroscopic implantation in the joint between the first metacarpal and the trapezium. The idea is that by avoiding violation of the joint capsule, patients will experience longer maintenance of joint stability, faster recovery and less pain.
In a statement issued by SBi, one of the company’s consulting surgeons, Dr. Randall Culp from Thomas Jefferson University in Philadelphia, said, “Arthroscopic implantation of an Artelon spacer is a good option for younger, more active, people who may be reluctant to undergo invasive surgery for a condition that is increasingly common among this group.”
And SBi’s CEO, Anthony Viscogliosi, points out that the device allows patients to undergo therapy earlier in the disease progression, and eliminates or minimizes the sacrifice of healthy tissue in other carpal metacarpal joint procedures that commonly include removal of the trapezium and harvesting tendon from the forearm.
Since being founded in 2005 by Viscogliosi Bros. — the musculoskeletal-focused venture capital firm created SBi by acquiring established companies in the orthopedic field, to create a single source of products for surgeons specializing in small bones and joints or limbs — the company has been on a role. Last year, it received five new FDA 510(k) clearances and completed eight M&A licensing and distribution deals; 19 new products were introduced. In April, SBi secured a $20 million debt facility financed by the Drawbridge Special Opportunities Fund.
Med Tech Sentinal is a regular contributor to BioHealthInvestor.com
________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- e-techblog
- Wishing Wealth
- Financial Skeptic
- Don't Mess With Taxes
- Millionaire Now! by Larry Nusbaum
- 360 Digest
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
The Swing of Things - Thu Jul 17, 2008 09:36AM
I used to make a pretty good living sharing hard won [read more]
I used to make a pretty good living sharing hard won [read more]
<< My Home | TheMoneyBlogs Home